| 2024-12-31 | Stryker Corporation | $16,314 | Debt forgiveness | Cash or cash equivalent | | | 2024 |
| 2024-12-31 | ENDOTRONIX, INC. | $8,850 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2024 |
| 2024-12-31 | Stryker Corporation | $3,458 | Long term medical supply or device loan | In-kind items and services | PRIME SERIES Device, PATIENT HANDLING - PH | | 2024 |
| 2024-12-31 | Stryker Corporation | $215 | Debt forgiveness | Cash or cash equivalent | | | 2024 |
| 2024-12-31 | Stryker Corporation | $190 | Long term medical supply or device loan | In-kind items and services | Stryker F1 Device, INSTRUMENTS | | 2024 |
| 2024-12-24 | Barco, Inc. | $93 | Food and Beverage | Cash or cash equivalent | | | 2024 |
| 2024-12-06 | Chiesi USA, Inc. | $3,983 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-11-25 | Gilead Sciences, Inc. | $154,704 | Grant | Cash or cash equivalent | | | 2024 |
| 2024-11-13 | Chiesi USA, Inc. | $6,116 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-11-13 | Chiesi USA, Inc. | $5,570 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-11-01 | Chiesi USA, Inc. | $4,200 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-10-23 | Chiesi USA, Inc. | $2,599 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-10-17 | Volta Medical Inc | $16,450 | Research payment | Cash or cash equivalent | VX1 Device, Cardiovascular | Companion AI | 2024 |
| 2024-09-26 | Boston Scientific Corporation | $1,921 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2024 |
| 2024-09-18 | Chiesi USA, Inc. | $1,384 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-08-31 | BIOTRONIK INC. | $213 | Debt forgiveness | Cash or cash equivalent | Selectra Device, Cardiology/Vascular Diseases | | 2024 |
| 2024-08-27 | Boston Scientific Corporation | $10,191 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2024 |
| 2024-08-14 | Chiesi USA, Inc. | $1,384 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-07-18 | Gilead Sciences, Inc. | $14,467 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2024 |
| 2024-06-26 | Chiesi USA, Inc. | $2,599 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-06-25 | Boston Scientific Corporation | $439 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2024 |
| 2024-06-05 | Chiesi USA, Inc. | $3,435 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-06-04 | KLS-Martin L.P. | $528 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE ORTHOANCHOR, SCREW, MAXDRIVE, DRILL FREE, 1.5 MM TISSUE COLLAR, 1.5 X 8 MM THD, TTL=13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2024 |
| 2024-06-04 | KLS-Martin L.P. | $176 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE ORTHOANCHOR, SCREW, MAXDRIVE, DRILL FREE, 1.5 MM TISSUE COLLAR, 2.0 X 10 MM THD, TTL=15 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2024 |
| 2024-06-04 | KLS-Martin L.P. | $176 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE ORTHOANCHOR, SCREW, MAXDRIVE, DRILL FREE, 2.0 MM TISSUE COLLAR, 2.0 X 8 MM THD, TTL=13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2024 |
| 2024-05-15 | Chiesi USA, Inc. | $8,715 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-05-10 | Chiesi USA, Inc. | $1,352 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-05-09 | Volta Medical Inc | $12,987 | Research payment | Cash or cash equivalent | VX1 Device, Cardiovascular | Tailored-AF | 2024 |
| 2024-03-22 | Boston Scientific Corporation | $2,500 | Grant | In-kind items and services | WATCHMAN Device, WATCHMAN Pro_IC | | 2024 |
| 2024-03-01 | PFIZER INC. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | | 2024 |
| 2024-02-28 | Novartis Pharmaceuticals Corporation | $10,060 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy | 2024 |
| 2024-02-22 | Novartis Pharmaceuticals Corporation | $69,576 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2024 |
| 2024-02-19 | Linvatec Corporation | $3,273 | Long term medical supply or device loan | In-kind items and services | MENISCAL REPAIR DEVICES Device, ORTHOPEDIC SURGERY | | 2024 |
| 2024-02-13 | Gilead Sciences, Inc. | $52,960 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir | 2024 |
| 2024-02-13 | Gilead Sciences, Inc. | $15,040 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir | 2024 |
| 2024-02-08 | Gilead Sciences, Inc. | $6,675 | Research payment | Cash or cash equivalent | Sunlenca Drug, HIV | Acceptability of Long-Acting Injectable Lenacapavir Among Heavily Treatment Experienced Individuals with HIV within the | 2024 |
| 2024-02-07 | Chiesi USA, Inc. | $7,250 | Research payment | Cash or cash equivalent | | A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du | 2024 |
| 2024-01-31 | Abbott Laboratories | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XIENCE ALPINE Device, Vascular | | 2024 |
| 2024-01-31 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2024 |
| 2024-01-22 | BIOTRONIK INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2024 |
| 2024-01-19 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2024 |
| 2024-01-17 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | | 2024 |
| 2024-01-16 | Boston Scientific Corporation | $4,000 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2024 |
| 2024-01-15 | Merck Sharp & Dohme LLC | $80,153 | Research payment | Cash or cash equivalent | ZERBAXA Drug, INFECTIOUS DISEASE | STUDY NAME#Impact of an Acute-Care Antimicrobial Stewardship Programs Interventional Collaboration on Antimicrobial Use | 2024 |
Comments